Rubius Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Rubius Therapeutics

11/05/2022 19:09

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 58 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Rubius Therapeutics Inc's reported EPS for the quarter was
a
loss of 58 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Rubius Therapeutics Inc shares had fallen by 73.3% this
quarter and lost 84.8% so far this year.
    * The company reported a quarterly loss of $52.41 million.
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 11 at 06:09 p.m.  ​All
figures in US dollars unless otherwise stated